Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: 604 + 0.39 + web  Related to the article below (Last Update: 8/4/2008)

Copper Mountain Mining Corporation - Exploration Update: Near ...
Canada NewsWire (press release), Canada - Jul 16, 2008
Additional information is available on the Company's web page at www.CuMtn.com. On behalf of the Board of COPPER MOUNTAIN MINING CORPORATION "Peter Holbek" ...CVE:CUM
West Coast Bancorp Reports 2008 Second Quarter Earnings
Earthtimes (press release), UK - Jul 21, 2008
The conference call may also be accessed by dialing (877) 604-2074. Conference ID#: 51095353 a few minutes prior to 11:00 am PDT . ...WCBO
Samuel Manu-Tech Inc. - Second quarter results
Canada NewsWire (press release), Canada - Jul 30, 2008
Omega is a recognized leader in the design, engineering, manufacturing and supply of open web steel joists used primarily in the commercial and industrial ...TSE:SMT
Positive Feasibility Study provides basis for Copper Mountain ...
CNW Telbec (Communiqu?s de presse), Canada - Jul 28, 2008
The initial five year average grade of mill feed is 0.39% Cu (0.43% Cu Equivalent) resulting in an average annual production of 96 million pounds copper for ...CVE:CUM
Trevali Continues to Intersect Broad Mineralized Intervals at ...
Trading Markets (press release), CA - Jul 23, 2008
For further details on the Company readers are referred to the Company's web site (www.trevaliresources.com) and to Canadian regulatory filings on SEDAR at ...
Source: Google News

Nonwoven web with projections -
SM Englebert, AL Wagner, GS Hafer, NJ Logsdon - US Patent 4,741,941, 1988 - freepatentsonline.com
... B,215,217,223 19/296,301,302 156/176,178,181,252,270,279 604/367,376,380,382,384,385
R. ... 5 was to form a web on a surface ... 2.0 2.0 13 21 0.5 0.8 0.39 0.52 0.183 ...

Contact Sex Signals on Web and Cuticle of Tegenaria atrica (Araneae, Agelenidae) -
O Prouvost, M Trabalon, M Papke, S Schulz - Archives of Insect Biochemistry and Physiology, 1999 - doi.wiley.com
... drumming 54 ? 38 59 ? 17 Duration (sec) Immobility 315 ? 91 604 ? 115* Palpal ...
Determination Web Cuticle Web Cuticle ... 1-eicosanol 0.76 (0.31) 0.39 (0.15) ...

… Credibility--Experience or Image?: A Survey on the Credibility of the World Wide Web in Germany in … -
W Schweiger - European Journal of Communication, 2000 - ejc.sagepub.com
... A Survey on the Credibility of the World Wide Web in Germany in Comparison to Other
Media ... Key Words Germany, media credibility, World Wide Web Introduction ...

[PDF] … particulate material and microbes by resuspension and their contribution to the planktonic food web -
MEP SERIES - MARINE ECOLOGY PROGRESS SERIES, 1990 - int-res.com
... Prog. Ser. Sediment-to-water fluxes of particulate material and microbes by
resuspension and their contribution to the planktonic food web Sam C. Wainright* ...

Implicit link analysis for small web search -
GR Xue, HJ Zeng, Z Chen, WY Ma, HJ Zhang, CJ Lu - Proceedings of the 26th annual international ACM SIGIR …, 2003 - portal.acm.org
... The original web-pages and link structure is downloaded from the website. ... link
Ratio 1 107 47 0.44 2 84 26 0.31 3 99 42 0.42 Average 0.39 ...

… dimethylsulfoniopropionate and dimethylsulfide cycling and the microbial food web in surface waters … -
R Simo, SD Archer, C Pedros-Alio, L Gilpin, CE … - Limnology and Oceanography, 2002 - JSTOR
... obtained from the mean of six experiments during the cruise (0.39 + 0.10 kgC ... 60.
Coupled dynamics of DMSP and food web MATRAI, PA, AND MD KELLER. ... 41: 595-604. ...

Web Mining and Online Visibility
N Schmidt-Manz, W Gaul - Classification-the Ubiquitous Challenge: Proceedings of the …, 2005 - books.google.com
... erotic service web sites (K={erotik, sex, porno}); a= 0.39, 0= 0.01 ... Real Needs: A
Study Analysis of User Queries on the Web. ... Journal of the ACM, 46 (5), 604-632 ...

Seasonal variation in the consumption of food by fish in the North Sea and implications for food web … -
SPR Greenstreet, AD Bryant, N Broekhuizen, SJ Hall … - ICES Journal of Marine Science: Journal du Conseil, 1997 - intl-icesjms.oxfordjournals.org
... 1997 Seasonal variation in the consumption of food by fish in the North Sea and
implications for food web dynamics ... Review of previous food web energy budgets ...

Spunlaced acrylic/polyester fabrics -
WK Kwok, JR Vincent? - US Patent 5,093,190, 1992 - freepatentsonline.com
... of Search: 15/209 R 28/105 428/288,297 604/378,383. ... 9060 1590 Absorbency Rate
(g/g/sec) 0.39 0.25 0 ... this example, the beneficial effects of higher web speeds ( ...

[BOOK] Web Database Applications with PHP and MySQL -
HE Williams - 2004 - books.google.com
... Code Overview 597 The Winestore Home Page 598 The Shopping Cart Implementation 604
Table of ... Guide 688 C. Mac OS X Installation Guide 698 D. Web Protocols 714 E ...

Source: Google Scholar
 
 

Scientists Harness Diptheria Toxin And Interleukin 2 To Help The Immune System Attack Melanoma

Article Date: 14 Nov 2006 - 9:00am (PST)

Researchers investigating ways of prompting the immune system to recognise and kill tumour cells have found that a drug containing parts of the diptheria toxin appears to work well in patients with advanced melanoma (skin cancer).

In the first part of a phase II clinical trial to test the drug denileukin diftitox (also known as DAB(389)IL2 or ONTAK) in melanoma, five out of seven patients with stage IV disease experienced significant regression or stabilisation of both tumours and metastases. The two other patients in whom the disease progressed were on a lower dose of the drug. All the patients are still alive after 12 months.

Dr Jason Chesney, associate director for translational research at the JG Brown Cancer Center, University of Louisville, Kentucky, USA, told a news briefing at the EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Prague on 9 November: "We are seeing some exciting results in stage IV melanoma patients whose median life expectancy is normally only about eight months. The phase II trial is continuing to examine the efficacy of denileukin diftitox in patients with melanoma."

Article continues below and (thank you)
 
The immune system that attacks cancer cells in humans depends on a balance between T cells, which specifically recognise and attack antigens such as tumour cells, and suppressive or regulatory T cells (Tregs), which turn off activated immune cells in order to prevent autoimmunity.

Dr Chesney explained: "Recently a subset of regulatory T cells has been found to directly suppress the activation of the anti-tumour T cells, but it was also discovered that, if the Tregs were depleted by targeting them with denileukin diftitox, then particular T cells in the immune system known as CD8+ T lymphocytes were able to attack and kill the melanoma cells in mice."

Denileukin diftitox is a fusion protein made up of amino acid sequences for the diptheria toxin and the T cell growth factor, interleukin 2 (IL2). It targets Tregs that have IL2 receptors on their cell surface, and it binds to part of the receptor called CD25. Once it reaches the inside of the cell it prevents protein synthesis, which leads to cell death within hours.

"We thought that if denileukin diftitox could selectively deplete Tregs in patients with melanoma, this would allow the CD8+ T cells to do their job of recognising and attacking the melanoma cells," said Dr Chesney.

Dr Chesney and his colleagues gave seven patients with stage IV melanoma nine or twelve micrograms per kilogram of body weight daily for four days, every three weeks for four cycles. The two patients on the lower dose had newly detectable tumours and tumour growth after two cycles. However, the five patients on the higher dose experienced significant regression of several metastatic tumours after four cycles, including subcutaneous tumours and metastases in the liver and lymph nodes.

One patient had two tumours on the leg that had died and became infected, requiring surgery. When the researchers examined the tumour tissue they found that it was surrounded by CD8+ T lymphocytes. "This meant that the lymphocytes had been successfully activated to attack the tumour, which consequently had died. We also found that the concentration of Tregs in this patient decreased by more than a half after the second day's dose of denileukin diftitox," said Dr Chesney.

"To our knowledge, this is the only trial to study the effects of Treg depletion in human cancer patients. From the results, we conclude that depleting Treg cells in patients with melanoma may allow the immune system to be activated successfully to kill cancer cells. These patients have survived longer than the median average life expectancy of a patient with stage IV melanoma.

"We also believe that, in the future, immunotherapies that depend on depleting Treg cells may prove to be useful in all types of cancer."

###

Abstract no: 264

1. EORTC [European Organisation for Research and Treatment of Cancer, NCI [National Cancer Institute], AACR [American Association for Cancer Research].

2. Incidence of melanoma has risen significantly in the past decade and now affects about one in 74 people in the USA. In 2006 it is expected to kill 41,000 people worldwide.

Contact: Emma Mason
European Organisation for Research and Treatment of Cancer
 

Advanced melanoma - Researchers test new therapy
Main Category: Cancer / Oncology News
Article Date: 06 Apr 2005 - 1:00 PST

Melanoma is a particularly deadly form of skin cancer very resistant to treatment. Researchers at H. Lee Moffitt Cancer Center & Research Institute and the University of South Florida are testing a promising new therapy that prompts the immune system to aid in the fight against melanoma tumors.

"This is a milestone clinical trial because it is the first time that electroporation is being used to deliver plasmid DNA in a gene therapy study in humans," said Richard Heller, PhD, USF professor of medical microbiology and immunology who helped develop the technology used in the study.

Electroporation is a technique in which a hand-held device applied to the skin delivers pulses of electricity to open up pores in the tumor cell membrane. This opening allows a small therapeutic molecule -- in this case a molecule known as a DNA plasmid that contains the gene for Interleukin-12 -- to slip inside the melanoma tumor before the membrane reseals.

"Melanoma does not respond well to standard chemotherapy," said Adil Daud, MD, assistant professor of oncology in the Cutaneous Oncology Program at Moffitt. "Gene therapy gives us the flexibility to introduce a huge variety of potential targets for treatment, but its major limitation has been getting the gene into the cancer. If electroporation can deliver the gene to these tumors reliably and without serious side effects, melanoma and other cancers would be open to many new treatment possibilities."

Six years of laboratory studies by Dr. Heller and his colleagues preceded the initial human trial begun earlier this year at Moffitt. The collaboration of USF and Moffitt in this trial is a good example of translational research -- moving the new application of a gene transfer technology from an animal model to the patient. Dr. Heller's team worked extensively with Dr. Daud to adapt the electroporation technique used on mice to humans.

The researchers injected the DNA plasmid, which encodes a gene that stimulates the immune system, directly into the tumor site in mice. Then, they applied electroporation to the site to help the plasmid move into the tumor cells. The tumor cells used the plasmid's genetic instructions to make proteins. These proteins signaled the immune system to recognize the melanoma tumors as abnormal and attack.

Eighty percent of the mice were cured with this therapy -- their tumors disappeared and the treated animals remained disease free for the full length of the study (100 days), Dr. Heller said.

Furthermore, he said, even when melanoma cells were reinjected into the cured mice the tumors were rejected. This indicates the immune system formed a memory response that recognized the melanoma cells as foreign and prevented tumor regrowth.

"We were very encouraged by the results of the preclinical studies." Dr. Heller said. "We're hoping this translates into a beneficial treatment for patients."

The Phase 1 clinical trial by Moffitt and Genetronics Biomedical Corp is evaluating the safety of the electroporation technology in treating patients with advanced melanoma. The trial expects to enroll 18 to 25 patients.

Contact: Anne DeLotto Baier
abaier@hsc.usf.edu
813-974-3300
University of South Florida Health Sciences Center
http://hsc.usf.edu

 

 

Research Finds Antioxidant Therapies Do Not Interfere With Radiation Treatment


Cancer patients can get the vital nutritional benefits from taking antioxidants without the risk of interfering with radiation treatment, according to research findings presented last weekend at the Society of Integrative Oncology's Third International Conference in Boston. The Society for Integrative Oncology is a non-profit organization of oncologists and other health professionals studying and integrating effective complementary therapies in cancer care.

The study, Effect of Concomitant Naturopathic Therapies on Clinical Tumor Response to External Beam Radiation Therapy for Prostate Cancer, was conducted by researchers at Cancer Treatment Centers of America and reviewed PSA levels of prostate cancer patients after receiving radiation therapy. Researchers found no difference between patients taking antioxidants and those who did not. Antioxidants used in the study included green tea extract, melatonin, high-potency multivitamins, vitamin C and vitamin E.

Cancer Treatment Centers of America chose this study to address clinical concerns about the use of dietary supplements in conjunction with conventional cancer therapies. The study addressed the concern that antioxidants might interfere with cancer cell oxidation levels that contribute to tumor killing by chemotherapy and radiation therapy.

"This study provides evidence that antioxidants as a complementary therapy in cancer treatment do not interfere with external beam radiation therapy," said Timothy Birdsall, ND, vice president of integrative medicine for Cancer Treatment Centers of America and lead author of the paper. "Antioxidants are one of many complementary and alternative medicine (CAM) therapies that are crucial in today's fight against cancer."

Treating cancer with advanced radiation, chemotherapy and surgery remains the best option for patients medically. But the side effects of these treatments can devastate a patient physically and emotionally. Through a fully integrated whole person care model, combining the best of traditional medicine with scientifically supported complementary and alternative therapies, cancer patients appear to be living a better quality of life.

"In cancer treatment today, we have to look beyond the traditional focus of treating only the tumor," Birdsall said.

"Cancer patients will be the first to tell you that's not enough. The integrated, whole person approach to cancer is highly valued, so much so that cancer patients and their caregivers are seeking out complementary or alternative therapies on their own."

More than 80 percent of cancer patients report using some sort of CAM treatmenti, many of them without medical supervision. Taking supplements without supervision, however, creates a huge patient safety risk. St. John's Wort, for example, is taken by some cancer patients to help lessen feelings of depression. But St. John's Wort can interfere with the effectiveness of some forms of chemotherapy, ultimately doing patients more harm than good.

John C. Williams, Jr., a prostate cancer survivor from Reidsville, GA, credits having fully integrated cancer care with helping him get through his cancer treatment. "I didn't know which was scarier, being diagnosed with cancer or when the doctor told me about the treatments," Williams said. "The whole person approach at Cancer Treatment Centers of America was my choice because they used nutrition, supplements, physical therapy and other therapies to help me keep my body, mind and spirit strong."

###

About Cancer Treatment Centers of America

Founded in 1988, Cancer Treatment Centers of America provides advanced Patient Empowerment MedicineSM through a network of cancer treatment hospitals and community oncology programs in Chicago, Tulsa, Seattle and Philadelphia. The facilities provide a comprehensive, patient-centered and multidisciplinary path to cancer care by integrating leading-edge medical treatments with support therapies such as nutrition, naturopathy, psychological counseling and spiritual support. For more information, visit http://www.cancercenter.com/.

Contact: Leigh Fazzina
Cancer Treatment Centers of America
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 
 © 2002-2006

Keywords::

Contact Iconocast

Home Page